A systematic approach to the diagnosis of suspected central nervous system lymphoma

JAMA Neurology

Volumn 70, Issue 3, 2013, Pages 311-319

  Scott, Brian J ^a   Douglas, Vanja C ^a   Tihan, Tarik ^b   Rubenstein, James L ^c   Josephson, S Andrew ^d  

^a Department of Neurology ^*  (United States)

^b Division of Neuropathology   (United States)

^c Division of Surgical Oncology   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CORTICOSTEROID; IMMUNOGLOBULIN HEAVY CHAIN; LACTATE DEHYDROGENASE ISOENZYME 5; MESSENGER RNA; MICRORNA; OLIGOCLONAL BAND; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

BONE MARROW BIOPSY; BRAIN BIOPSY; CENTRAL NERVOUS SYSTEM LYMPHOMA; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID CYTOLOGY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOHISTOCHEMISTRY; LEPTOMENINX; LEPTOMENINX LYMPHOMA; LYMPHOMA; MOLECULAR DIAGNOSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; PROTEOMICS; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; TESTIS LYMPHOMA; VITREOUS BIOPSY;

EID: 84874898496     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.606     Document Type: Review

References (79)

1. Buhring U, Herrlinger U, Krings T, Thiex R, Weller M, Kuker W. MRI features of primary central nervous system lymphomas at presentation. Neurology. 2001; 57(3):393-396.
2. Coulon A, Lafitte F, Hoang-Xuan K, et al. Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol. 2002;12 (2):329-340.
3. Jellinger KA, Paulus W. Primary central nervous system lymphomas an update. J Cancer Res Clin Oncol. 1992;119(1):7-27.
4. Lachance DH, O'Neill BP, Macdonald DR, et al. Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature. Neurology. 1991;41(1):95-100.
5. Fischer L, Martus P, Weller M, et al. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology. 2008;71(14): 1102-1108.
6. Balmaceda C, Gaynor JJ, Sun M, Gluck JT, DeAngelis LM. Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications. Ann Neurol. 1995;38(2):202-209.
7. Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg. 2000;92(2):261-266.
8. Peterson K, Gordon KB, Heinemann MH, DeAngelis LM. The clinical spectrum of ocular lymphoma. Cancer. 1993;72(3):843-849.
9. O'Neill BP, Dinapoli RP, Kurtin PJ, Habermann TM. Occult systemic nonHodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough J Neurooncol. 1995;25(1):67-71.
10. Mohile NA, Deangelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol. 2008;10(2):223228.
11. Bromberg JE, Breems DA, Kraan J, et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology. 2007;68 (20):1674-1679.
12. Hunt MA, Jahnke K, Murillo TP, Neuwelt EA. Distinguishing primary central nervous system lymphoma from other central nervous system diseases: a neurosurgical perspective on diagnostic dilemmas and approaches. Neurosurg Focus. 2006;21(5):E3. http://thejns.org/doi/abs/10.3171/foc.2006.21.5.4. Accessed October 20, 2011.
13. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med. 1993;119(11):1093-1104.
14. Ferreri AJ. How I treat primary CNS lymphoma. Blood. 2011;118(3):510-522.
15. Zhang D, Hu LB, Henning TD, et al. MRI findings of primary CNS lymphoma in 26 immunocompetent patients. Korean J Radiol. 2010;11(3):269-277.
16. Johnson BA, Fram EK, Johnson PC, Jacobowitz R. The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. AJNR Am J Neuroradiol. 1997;18(3):563-572.
17. Hayakawa T, Takakura K, Abe H, et al. Primary central nervous system lymphoma in Japan a retrospective, co-operative study by CNS-Lymphoma Study Group in Japan. J Neurooncol. 1994;19(3):197-215.
18. Baumgartner JE, Rachlin JR, Beckstead JH, et al. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg. 1990;73(2): 206-211.
19. Antinori A, Ammassari A, De Luca A, et al. Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology. 1997;48(3):687-694.
20. Thurnher MM, Rieger A, Kleibl-Popov C, et al. Primary central nervous system lymphoma in AIDS: a wider spectrum of CT and MRI findings. Neuroradiology. 2001;43(1):29-35.
21. Haldorsen IS, Krakenes J, Goplen AK, Dunlop O, Mella O, Espeland A. AIDSrelated primary central nervous system lymphoma: a Norwegian national survey 1989-2003. BMC Cancer. 2008;8:225. doi:10.1186/1471-2407-8-225.
22. Haldorsen IS, Espeland A, Larsson EM. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol. 2011;32(6):984-992.
23. Antinori A, De Rossi G, Ammassari A, et al. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol. 1999;17(2):554-560.
24. O'Malley JP, Ziessman HA, Kumar PN, Harkness BA, Tall JG, Pierce PF. Diagnosis of intracranial lymphoma in patients with AIDS: value of 201Tl singlephoton emission computed tomography. AJR Am J Roentgenol. 1994;163 (2):417-421.
25. Ruiz A, Ganz WI, Post MJ, et al. Use of thallium-201 brain SPECT to differentiate cerebral lymphoma from toxoplasma encephalitis in AIDS patients. AJNR Am J Neuroradiol. 1994;15(10):1885-1894.
26. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995;38(1): 51-57.
27. Chamberlain MC, Sandy AD, Press GA. Leptomeningeal metastasis: a comparison of gadolinium-enhancedMRand contrast-enhanced CT of the brain. Neurology. 1990;40(3, pt 1):435-438.
28. Geppert M, Ostertag CB, Seitz G, Kiessling M. Glucocorticoid therapy obscures the diagnosis of cerebral lymphoma. Acta Neuropathol. 1990;80(6):629-634.
29. Weller M. Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol. 1999;43(3):237-239.
30. Bromberg JE, Siemers MD, Taphoorn MJ. Is a "vanishing tumor" always a lymphoma Neurology. 2002;59(5):762-764.
31. Zaki HS, Jenkinson MD, Du Plessis DG, Smith T, Rainov NG. Vanishing contrast enhancement in malignant glioma after corticosteroid treatment. Acta Neurochir (Wien). 2004;146(8):841-845.
32. A predictive model for aggressive non-Hodgkin's lymphoma: the International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329(14):987-994.
33. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma: international prognostic index. Blood. 2004;104(5):1258-1265.
34. Hoster E, Dreyling M, Klapper W, et al German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008; 111(2):558-565.
35. Di Noto R, Scalia G, Abate G, et al. Critical role of multidimensional flow cytometry in detecting occult leptomeningeal disease in newly diagnosed aggressive B-cell lymphomas. Leuk Res. 2008;32(8):1196-1199.
36. WellerM, Stevens A, Sommer N, Schabet M, Wietholter H. Humoral CSF parameters in the differential diagnosis of hematologic CNS neoplasia. Acta Neurol Scand. 1992;86(2):129-133.
37. Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105(2):496-502.
38. Quijano S, López A, Manuel Sancho J, et al; Spanish Group for the Study of CNS Disease in NHL. Identification of leptomeningeal disease in aggressive B-cell nonHodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol. 2009; 27(9):1462-1469.
39. Yoshida S, Morii K, Watanabe M, Saito T. Characteristic features of malignant lymphoma with central nervous system involvement. Surg Neurol. 2000;53 (2):163-167.
40. Lossos IS, Breuer R, Intrator O, Lossos A. Cerebrospinal fluid lactate dehydrogenase isoenzyme analysis for the diagnosis of central nervous system involvement in hematooncologic patients. Cancer. 2000;88(7):1599-1604.
41. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50(1):121-127.
42. Psimaras D, Carpentier AF, Rossi C; PNS Euronetwork. Cerebrospinal fluid study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry. 2010;81(1): 42-45.
43. Ernerudh J, Olsson T, Berlin G, von Schenck H. Cerebrospinal fluid immunoglobulins and 2-microglobulin in lymphoproliferative and other neoplastic diseases of the central nervous system. Arch Neurol. 1987;44(9):915920.
44. Perske C, Nagel I, Nagel H, Strik H. CSF cytology the ongoing dilemma to distinguish neoplastic and inflammatory lymphocytes. Diagn Cytopathol. 2011; 39(8):621-626.
45. Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82(4):733739.
46. Mavlight GM, Stuckey SE, Cabanillas FF, et al. Diagnosis of leukemia or lymphoma in the central nervous system by beta2-microglobulin determination. N Engl J Med. 1980;303(13):718-722.
47. Koch TR, Lichtenfeld KM, Wiernik PH. Detection of central nervous system metastasis with cerebrospinal fluid beta-2-microglobulin. Cancer. 1983;52(1): 101-104.
48. Subhash MN, Rao BS, Shankar SK. Changes in lactate dehydrogenase isoenzyme pattern in patients with tumors of the central nervous system. Neurochem Int. 1993;22(2):121-124.
49. Cinque P, BryttingM, Vago L, et al. Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet. 1993;342(8868):398-401.
50. De Luca A, Antinori A, Cingolani A, et al. Evaluation of cerebrospinal fluid EBVDNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma. Br J Haematol. 1995;90(4):844-849.
51. Roberts TC, Storch GA. Multiplex PCR for diagnosis of AIDS-related central nervous system lymphoma and toxoplasmosis. J Clin Microbiol. 1997;35(1):268269.
52. Cingolani A, De Luca A, Larocca LM, et al. Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. J Natl Cancer Inst. 1998;90(5):364-369.
53. Cavaliere R, Petroni G, Lopes MB, Schiff D; International Primary Central Nervous System Lymphoma Collaborative Group. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group report. Cancer. 2010; 116(4):863-870.
54. Ivers LC, Kim AY, Sax PE. Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma. Clin Infect Dis. 2004; 38(11):1629-1632.
55. Yamada M, Hudson S, Tournay O, et al. Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third- complementaritydetermining region (CDR-III)-specific probes. Proc Natl Acad Sci U S A. 1989; 86(13):5123-5127.
56. Rhodes CH, Glantz MJ, Glantz L, et al. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer. 1996;77(3):543-548.
57. Baehring JM, Hochberg FH, Betensky RA, Longtine J, Sklar J. Immunoglobulin gene rearrangement analysis in cerebrospinal fluid of patients with lymphoproliferative processes. J Neurol Sci. 2006;247(2):208-216.
58. Gleissner B, Siehl J, Korfel A, Reinhardt R, Thiel E. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology. 2002; 58(3):390-396.
59. Roy S, Josephson SA, Fridlyand J, et al. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008;26(1):96-105.
60. Lawrie CH. MicroRNAs and haematology: small molecules, big function. Br J Haematol. 2007;137(6):503-512.
61. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumourassociated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141(5):672-675.
62. Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117(11):3140-3146.
63. Grimm SA, McCannel CA, Omuro AM, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group report. Neurology. 2008;71(17):1355-1360.
64. Hormigo A, DeAngelis LM. Primary ocular lymphoma: clinical features, diagnosis, and treatment. Clin Lymphoma. 2003;4(1):22-29.
65. Read RW, Zamir E, Rao NA. Neoplastic masquerade syndromes. Surv Ophthalmol. 2002;47(2):81-124.
66. Eichler AF, Batchelor TT. Primary central nervous system lymphoma: presentation, diagnosis and staging. Neurosurg Focus. 2006;21(5):E15. http://thejns.org/doi/pdf/10.3171/foc.2006.21.5.16. Accessed January 11, 2011.
67. Grimm SA, Pulido JS, Jahnke K, et al. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group report. Ann Oncol. 2007;18(11):1851-1855.
68. Velez G, Chan CC, Csaky KG. Fluorescein angiographic findings in primary intraocular lymphoma. Retina. 2002;22(1):37-43.
69. Sherman ME, Erozan YS, Mann RB, et al. Stereotactic brain biopsy in the diagnosis of malignant lymphoma. Am J Clin Pathol. 1991;95(6):878-883.
70. Air EL, Leach JL, Warnick RE, McPherson CM. Comparing the risks of frameless stereotactic biopsy in eloquent and noneloquent regions of the brain: a retrospective review of 284 cases. J Neurosurg. 2009;111(4):820-824.
71. Woodworth GF, McGirt MJ, Samdani A, Garonzik I, Olivi A, Weingart JD. Frameless image-guided stereotactic brain biopsy procedure: diagnostic yield, surgical morbidity, and comparison with the frame-based technique. J Neurosurg. 2006;104(2):233-237.
72. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9-17.
73. Ferreri AJ, Reni M, Zoldan MC, Terreni MR, Villa E. Importance of complete staging in non-Hodgkin's lymphoma presenting as a cerebral mass lesion. Cancer. 1996;77(5):827-833.
74. la Fougère C, Hundt W, Brockel N, et al. Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and nonHodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2006;33(12):1417-1425.
75. Zucca E, Conconi A, Mughal TI, et al International Extranodal Lymphoma Study Group. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21(1):20-27.
76. Abrey LE, Batchelor TT, Ferreri AJ, et al International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034-5043.
77. Baehring JM, Hochberg EP, Raje N, Ulrickson M, Hochberg FH. Neurological manifestations of Waldenstrom macroglobulinemia. Nat Clin Pract Neurol. 2008; 4(10):547-556.
78. Ahluwalia MS, Wallace PK, Peereboom DM. Flow cytometry as a diagnostic tool in lymphomatous or leukemic meningitis: ready for prime time Cancer. 2012; 118(7):1747-1753.
79. OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index. aspx o=5653. Accessed November 27, 2012.